Skip to main content

Table 2 Characteristics at study enrollment of HIV-infected children not receiving ART

From: Barriers to the care of HIV-infected children in rural Zambia: a cross-sectional analysis

  Total (n = 138) Children not eligible for ARTc (n = 53) Children eligible for ART at study enrollment (n = 79)
Median age (yrs) (IQR) a 3.3 (1.8, 6.7) 3.6 (2.5, 6.7) 2.3 (1.3, 6.7)
Male (%) 55 (40) 20 (38) 34 (43)
Length of time (months) since enrolling in ART clinic 3.2 (0.5, 10.1) 3.8 (0.2, 11.7) 2.8 (0.4, 9.0)
Median WAZ (IQR) (n = 120) a,b -2.2 (-3.2, -1.3) -2.1 (-2.7, -1.0) -2.4 (-3.5,-1.6)
   WAZ <-2 66 (55) 25 (53) 41 (59)
   WAZ ≥-2 54 (45) 22 (47) 28 (41)
Median CD4 + T cell % (IQR) (n = 122) a 20.7 (16.0, 30.0) 29.6 (23.2, 36.9) 17.4 (12.1, 21.1)
Median CD4 + T cell count (IQR) (n = 126) a 815 (455, 1372) 980 (578, 1434) 735 (377, 1287)
Severe immunodeficiency a,d 47 (37) 0 (0.0) 47 (64)
Median total lymphocyte count (IQR) (n = 73) 4266 (2238, 7025) 3289 (2179, 4847) 4464 (2328, 7236)
Median hemoglobin (IQR) (n = 110) a 10.5 (9.2,11.6) 11.3 (9.8,11.7) 10.1 (8.8, 11.3)
   Hemoglobin <8 gm/dL 6 (5) 1 (3) 5 (7)
   Hemoglobin ≥8 gm/dL 104 (95) 36 (97) 68 (93)
WHO stage (n = 101) a    
   1 17 (16) 11 (34) 5 (7)
   2 33 (32) 21 (66) 10 (14)
   3 38 (37) 0 (0) 38 (55)
   4 16 (15) 0 (0) 16 (23)
  1. ART = antiretroviral therapy; IQR = interquartile range; WAZ = weight-for-age Z score; WHO = World Health Organization
  2. a p < 0.05 for difference between children eligible and ineligible for ART at study enrollment
  3. b for children <10 yrs old
  4. c eligibility for ART determined based on the 2006 WHO treatment guidelines; 6 children could not be classified as WHO stage and laboratory results were not available at baseline
  5. d severe immunodeficiency defined by age according to WHO guidelines